Previous 10 | Next 10 |
Koonsiri Boonnak/iStock via Getty Images GM (GM) took its turn in the spotlight during Friday's midday action. The carmaker announced a recall of its Chevy Volt electric vehicles due to fire concerns. Meanwhile, earnings news remained a key driver in intraday trading. Both South State (SSB) a...
Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...
Shares of Arvinas (NASDAQ: ARVN) rallied nearly 10% during Thursday's trading session, in response to the announcement of a new collaboration with drug giant Pfizer (NYSE: PFE) . The two companies will co-develop and then co-market Arvinas' ARV-471, currently in trials as a ...
Arvinas (ARVN) perks up 3.8% premarket after collaborating with Pfizer (PFE) to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor ((ER)) protein degrader.Under the terms of the agreement, Pfizer will pay Arvinas $650M...
– Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics – – ARV-471 is currently in Phase 2 development for the treatment of patients with local...
Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...
NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined state and local officials, fellow tenants, and community partners, in a groundbreaking c...
NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer...
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. Oncology companies get ready to present new data at the largest US oncology conference with potential fo...
Gainers: [[RPHM]] +11.9%. [[BLI]] +6%. [[ARVN]] +5.6%. [[BKEPP]] +3.9%. [[LAKE]] +3.1%.Losers: [[OLED]] -7.2%. [[LMNL]] -5.2%. [[PXLW]] -3.7%. [[FUTU]] -3%. [[AGLE]] -2.3%. For further details see: OLED, FUTU, LAKE and BLI among after-hours movers
News, Short Squeeze, Breakout and More Instantly...
NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of d...
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of...
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer....